Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06824220

Effect of High-Flow Tracheal Oxygen on EELI

Effect of High-Flow Tracheal Oxygen on End-Expiratory Lung Impedance in Tracheostomized Patients

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
11 (estimated)
Sponsor
Argentinian Intensive Care Society · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this analytical experimental study is to evaluate whether high-flow tracheal oxygen therapy at flow rates above 60 L/min increases end-expiratory lung impedance in tracheostomized patients in the intensive care unit. The main question it aims to answer is whether high-flow tracheal oxygen therapy improves end-expiratory lung impedance in tracheostomized patients. This study will be conducted in the Intensive Care Unit of Sanatorio Parque in Rosario, Santa Fe, Argentina, between December 1, 2024, and March 31, 2025. The participant population consists of adult ICU patients (≥18 years old) who are tracheostomized, have undergone at least 10 days of mechanical ventilation, and can tolerate spontaneous breathing for at least 12 hours. By analyzing the effects of high-flow tracheal oxygen therapy on lung function, this study aims to generate valuable insights into its physiological impact, potentially influencing clinical management strategies for tracheostomized patients in intensive care settings.

Conditions

Interventions

TypeNameDescription
DEVICEHigh-Flow Tracheal OxygenHigh-Flow Tracheal Oxygen is the use of high oxygen flows in tracheostomized patients. Unlike conventional oxygen therapy which is performed through siliconized nasal prongs, this is done through a connector directly on the tracheostomy tube.

Timeline

Start date
2024-12-01
Primary completion
2025-03-31
Completion
2025-03-31
First posted
2025-02-13
Last updated
2025-02-13

Locations

1 site across 1 country: Argentina

Source: ClinicalTrials.gov record NCT06824220. Inclusion in this directory is not an endorsement.